Rimidi and Eli Lilly and Company are partnering to develop provider-focused tools that will integrate personalized solutions for people who use insulin to manage their diabetes. Under the partnership, Rimidi will integrate its diabetes management software platform with Lilly’s integrated insulin management system in development.

The non-exclusive agreement will aim to make diabetes management easier for the approximately 30 million Americans by helping people use insulin more effectively while optimizing diabetes management within the normal clinical workflow.

“Diabetes management is a collaborative effort between people with diabetes and their healthcare providers. With the right support they can achieve better results together,” said Lucienne Ide, MD, PhD, chief executive officer of Rimidi. “We are proud to partner with Lilly to facilitate personalized management of diabetes. This is a ‘better together’ story.”

Rimidi’s platform helps clinicians personalize care by leveraging the individual characteristics and clinical histories of people with diabetes to identify individuals who may benefit from specific management approaches. Lilly’s integrated insulin management system combines a connected insulin pen with glucose-sensing technologies (e.g., glucose meter, CGM) and software applications to deliver personalized insulin dose recommendations. Data from these devices and apps will flow back to physicians.